References

1. United States Patent and Trademark Office. U.S. Patent Application No. 2007/0259039A1; November 8, 2007. http://appft.uspto.gov/. Accessed March 23, 2016.

2. Del Rosso JQ. Weight-based Dosing and Extended-release Formulation of Minocycline Tablets. Is There Clinical Significance? J Clin Aesthet Dermatol. 2009;2(1):44-7.

3. Plott RT, Wortzman MS. Key bioavailability features of a new extended-release formulation of minocycline hydrochloride tablets. Cutis. 2006;78(suppl 4):6-10.

4. Fleischer AB, Dinehart S, Stough D, et al. Safety and Efficacy of a New Extended Release Formulation of Minocycline. Cutis. 2006;78(suppl 4):21-31.

5. XIMINO [prescribing information]. Scottsdale, AZ. Journey Medical Corporation; 2019.